Merck, Schering Merger Puts Pressure On Regulators

By Jacqueline Bell (March 9, 2009, 12:00 AM EDT) -- Merck & Co.'s plan to merge with Schering-Plough Corp. in a $41.1 billion deal announced Monday is prompting questions over how antitrust regulators will tackle the second proposal in as many months to combine two pharmaceutical industry giants.

The Merck and Schering deal comes just six weeks after Pfizer Inc. revealed its own plans to take over Wyeth Inc. in a deal valued at $68 billion.

Many U.S. drugmakers are facing patent expirations of a number of their blockbuster drugs in the next few years, and there are few replacement drugs in the research and development pipeline ready to take their...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!